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Abstract 3-Phosphoglycerate dehydrogenase (3-PGDH)
deficiency is considered to be a rare cause of congenital
microcephaly, infantile onset of intractable seizures and severe
psychomotor retardation. Here, we report for the first time a
very mild form of genetically confirmed 3-PGDH deficiency
in two siblings with juvenile onset of absence seizures and
mild developmental delay. Amino acid analysis showed serine
values in CSF and plasma identical to what is observed in the
severe infantile form. Both patients responded favourably to
relatively low dosages of serine supplementation with cessa-
tion of seizures, normalisation of their EEG abnormalities and
improvement of well-being and behaviour. These cases
illustrate that 3-PGDH deficiency can present with mild
symptoms and should be considered as a treatable disorder in
the differential diagnosis of mild developmental delay and
seizures. Synopsis: we present a novel mild phenotype in
patients with 3-PGDH deficiency.
Introduction
3-Phosphoglycerate dehydrogenase deficiency (OMIM
#601815) is an autosomal recessive disorder caused by a
defect in the synthesis of the amino acid L-serine. The
disorder was first reported by Jaeken and colleagues in
1996 in two patients with congenital microcephaly, intrac-
table seizures and severe psychomotor retardation (Jaeken
et al. 1996). After this initial report, additional patients were
documented in the literature and from these reports a rather
homogeneous clinical phenotype evolved (de Koning et al.
1998; de Koning 2006; Hausler et al. 2001; Jaeken et al.
1996; Pind et al. 2002; Pineda et al. 2000). All patients
except one, presented with congenital microcephaly indic-
ative of the fact that in the majority of patients the
symptoms already occurred before birth. Affected infants
developed intractable seizures within weeks to months after
birth and showed little to no psychomotor development.
Finally, a severe spastic quadriplegia becomes evident
during the first years of life. In addition, the patients were
irritable, hypertonic, had feeding difficulties and appeared
to be “unhappy” infants. EEG recordings showed several
seizure types, including hypsarithmia and multifocal epi-
leptic activity (de Koning et al. 2002). Cranial MRI scans
showed a striking absence of white matter volume and
hypomyelination (de Koning et al. 2000). In the patients
with this severe infantile phenotype the response to oral
treatment with L-serine sometimes combined with glycine
was favourable with respect to their well-being and
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seizures. In some patients the seizures completely resolved
while in others seizures reappeared after some period, albeit
in a lower frequency. The results of amino acid treatment
on the progression of psychomotor development, however
were very disappointing, with little to none progression of
psychomotor development in symptomatic patients during
long term follow-up (de Koning 2006).
In this paper we present a family with a hitherto
unreported very mild phenotype of 3-PGDH deficiency,
expanding the clinical phenotype to that of juvenile onset of
seizures with mild psychomotor retardation.
Case reports
Two children, a boy and a girl, were born to healthy
nonconsanguineous Dutch parents. In the boy the pregnancy
was complicated by intrauterine growth retardation. At birth,
his height was 48 cm (3rd centile), weight 2600 grams (3rd
centile) and head circumference 33 cm (3rd centile). He was
slow in acquiring early developmental milestones (pulls to
stand at 10 months, first words at 18 months, walking at
24 months) and after three years of age developmental delay
became evident. At the age of nine years he presented with
absence seizures (complex typical absences) and his EEG
recording showed bilateral synchronous spike-wave com-
plexes, which were enhanced after hyperventilation with
typical 3 Hz spike wave complexes. His absence seizures
were successfully treated with ethosuximide. An attempt of
ethosuximide withdrawal at the age of 15 years was
unsuccessful. He visits a secondary school for children with
learning difficulties and is actively involved in sports.
At the time of diagnosis he was 16 years old and
demonstrated hyperactive behaviour and mild developmen-
tal delay with an IQ of 49. His head circumference was
55 cm (10th centile) whereas his height and weight were
both at the 75th centile. His neurological exam was
unremarkable except for a subtle bilateral ankle clonus. In
addition, he had generalised hyperlaxity of large and small
joints and striae rubra on his abdomen and upper legs. His
cranial MRI revealed no abnormalities. Laboratory inves-
tigations were performed in this family because the parents
requested genetic counselling for familial seizures. Exten-
sive investigations revealed no abnormalities, except that
his plasma serine was at the lower end of the normal range
(63 μmol/L, reference range 70-174) with a normal value
for glycine (252 μmol/L, reference 147-321). However, his
cerebrospinal fluid (CSF) serine concentration was severely
reduced with a value of 9 μmol/L (reference 17-41) again
with a normal value for glycine (5 μmol/L, reference 2-13).
He was treated with oral L-serine supplementation starting
in a relatively low dose of 4 times 2 grams/day which was
later increased to 4 times 3 grams/day (140 mg/kg/day)
(Table 1). Significant improvement in general well-being,
physical fitness and behaviour were noted within weeks after
starting the amino acid therapy and subsequently his absence
seizures disappeared. During a three years follow-up his
EEG recordings remained free of epileptic activity and
ethosuximide medication was successfully discontinued. The
values of CSF and plasma serine normalised during
treatment. His CSF serine rose from 9 to 29 μmol/L after
4 months of treatment. Developmental testing showed no
progress in IQ score (IQ 50).
His sister was 15 years old at the time of diagnosis. She was
born after an uneventful pregnancy with a normal head
circumference, weight and height. Her early developmental
milestones were normal, but developmental delay became
evident after four years of age. Similar to her brother, she
presented with absence seizures, albeit at an earlier age of five
years. Her EEG also showed the typical 3 Hz bilateral
synchronous spike-wave complexes, but with a more frontal
predilection. She was treated with ethosuximide and levatir-
acetam, but despite this had daily absences. She suffered from
significant behavioural problems and mood disturbances. In
addition to her neurological and behavioural complaints she
had severe adiposity and used a wheelchair, because of pain in
feet, ankles and knees. The latter complaints were likely
caused by generalised hyperlaxity in combination with severe
obesity. Prader –Willi syndrome was ruled out by means of
molecular testing. Upon formal developmental testing her IQ
was shown to be 55.
Her head circumference was 57 cm (75th centile), her
height was 173 cm and weight 99 kg (19 kg above the 98th
centile). Her neurological exam was unremarkable, exclud-
ing a neurological cause for her pain symptoms. The latter
was further supported by a normal EMG. MRI of the brain
showed normal results. She also had striae rubra on lower
abdomen and upper legs similar to her brother. Amino acid
analysis showed a low plasma serine concentration
(56 μmol/L, reference 70-174), with a glycine value in
the normal range (175 μmol/L, reference 147-321). The girl
refused to undergo a lumbar puncture to obtain pre-
treatment CSF amino acid values.
She was treated with 4 times 3 grams L-serine/day
(120 mg/kg/day) (Table 1). Follow-up revealed a significant
improvement in behaviour, ambulance and quality of life.
Absences stopped, both anti-epileptic drugs were discon-
tinued and her follow-up EEG was free of epileptic activity.
During treatment normal values for plasma and CSF serine
were obtained. Repeated developmental testing showed no
change in IQ score.
In both children the amino acid therapy was well
tolerated and no side effects were reported during the three
years follow-up. Enzymatic analysis of 3-PGDH activity in
cultured skin fibroblasts displayed a deficient value in both
patients (6.8 and 3.1 respectively normal values 33.1±1.9
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(nmol/min.mg protein)), results that were comparable to
what was reported in patients with the severe infantile
phenotype of 3-PGDH deficiency (Tabatabaie et al. 2009).
Mutation analysis of the PHGDH gene confirmed a
homozygous c.1129 G>A (p.G377S) mutation in both
children. Both parents were shown to be carriers of the
mutation confirming autosomal recessive inheritance. The
details of the molecular analysis were published elsewhere
(Tabatabaie et al. 2009).
Discussion
This is the first report of a mild form of 3-PGDH deficiency
and expands the clinical spectrum of this disorder towards
that of a juvenile onset of (absence) seizures and develop-
mental delay. As demonstrated by both children, micro-
cephaly, developmental arrest, spastic tetraplegia and
hypomyelination are not necessarily present in 3-PGDH
deficiency. In our opinion, L-serine deficiency should be
considered in the differential diagnosis of children with
developmental delay and seizures.
This family underscores once more the importance of
amino acid analysis in the diagnosis of treatable forms of
seizures and the need to recognise the significance of low
or borderline low values of plasma serine. Because of the
influence of dietary amino acids in particular on plasma
values, amino acid analysis need to be performed in a fasted
state. According to our own (unpublished) data the effects
of a single oral load (100 mg/kg) with either serine or
glycine results in a steep rise with a peak concentration
between 1-2 hours after loading. Amino acid values return
to normal after 4 hours post loading. From this we
concluded that in daily practice preferentially amino acids
should be analysed after an overnight fast, but otherwise
that it would probably be safe to analyse plasma amino
acids 4-6 hours after meals. For CSF a single amino acid
loading (100 mg/kg) only marginally influenced CSF serine
and values only rose after repeated doses over a period of
weeks to months of treatment. Therefore, we consider the
influence of meals on CSF serine to be very limited and for
this reason remain the preferred diagnostic procedure to
confirm serine deficiency.
It was striking that the patients reported here dis-
played biochemical abnormalities indistinguishable from
those with the severe phenotype. Their plasma and CSF
serine values were in the same range as what was
observed in severely affected infants. The same was true
for the 3-PGDH enzyme activity in cultured skin
fibroblasts showing a residual activity comparable to
that in patients with the infantile phenotype (Tabatabaie
et al. 2009). It is obvious that the mild clinical phenotype
could not be predicted from the biochemical or molecular
analysis and that additional genetic or environmental
factors considerably modulate disease severity in serine
deficiency. Of particular interest was the fact that these
two patients were effectively treated with much lower
dosages of L-serine compared to patients with the
infantile phenotype. This is remarkable, as we showed
earlier that low dosages of L-serine failed to result in
clinical and biochemical improvement in patients with
the infantile form (de Koning et al. 1998). Therefore, we
should revise our former treatment recommendations and
add to this that in patients with a mild phenotype a dose of
L-serine of 120-150 mg/kg/day is likely to be sufficient
(de Koning 2006).
Table 1 Comparison of clinical and biochemical features in infantile and juvenile 3-PGDH deficiency
Infantile 3-PGDH deficiency Juvenile 3-PGDH deficiency
Clinical features Congenital Microcephaly, severe psychomotor retardation,
intractable seizures, irritable and spasticity
Absence seizures, moderate
developmental delay behavioural
abnormalities Joint laxicity and striae
Occasionally megaloblastic anemia cataracts, hypogonadism,
adducted thumbs, inguinal and umbilical hernias
CSF serine (μmol/L) 6-8 9* (reference 17-41)
CSF glycine (μmol/L) 1-4 5* (reference 2-13)
Plasma serine (μmol/L) 28-64 63 and 56 (reference 70-174)
Plasma glycine (μmol/L) 128-190 252 and 175 (reference 147-321)
Residual enzymatic activity
(nmol/min.mg protein)
3,1-7,3 6,8 and 3,1 (reference 33,1±1,9)
Treatment 500-700 mg L-serine/kg/day and 200-300 mg glycine/kg/day 100-150 mg L-serine/kg/day
Response to treatment Control of seizures in some, lowered seizure frequency in all
patients, no progression of psychomotor development
Control of seizures, correction
of behavioural abnormalities
CSF = cerebrospinal fluid, * measured only in the boy
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In this family both children presented with absence
seizures, but it remains to be determined whether this
seizure type is specific for this mild form. In the severe
infantile phenotype, different clinical seizure patterns and
EEG abnormalities were documented, none of which was
specific for the disorder or disease progression. Therefore,
it seems reasonable to assume that other generalised
epilepsies can be present in milder forms of 3-PGDH
deficiency. Furthermore, it also needs to be established
whether the joint laxity and skin abnormalities are
consistent findings of this mild phenotype. These symptoms
have not been reported earlier in serine deficiency, but striae
rubrae are not very rare in adolescents, which could mean that
this is merely a coincidental finding.
Conclusions
We have shown that the clinical spectrum of phosphoglycerate
dehydrogenase deficiency includes a milder form, with
juvenile onset of seizures and an excellent response to
treatment with L-serine. These patients were biochemically
indistinguishable from those with the severe infantile form
and the mild clinical phenotype could not be predicted by
biochemical or molecular analysis. This family with juvenile
3-PGDH deficiency once again emphasizes the importance of
careful interpretation of (low-borderline) amino acid concen-
trations and early detection of serine deficiency.
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